Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Virax Biolabs GroupVRAX +15.94%45 EV-to-EBIT is 0.63 as of Aug. 20, 2026, which is 110% above its 10-year median of 0.30. GuruFocus rates VRAX with a GF Score™ of 45/100 and a GF Value™ of $3.58 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 369 Biotechnology companies, Virax Biolabs Group ranks better than 83.74% on this metric.
Virax Biolabs Group (NAS:VRAX) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Virax Biolabs Group's Enterprise Value for the quarter that ended in Mar. 2026 was $-3.08 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Virax Biolabs Group's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-5.87 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Virax Biolabs Group EV-to-EBIT Related Terms
Virax Biolabs Group EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Virax Biolabs Group's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Virax Biolabs Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Virax Biolabs Group EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Virax Biolabs Group's EV-to-EBIT falls into.
Virax Biolabs Group's current Enterprise Value is $-3.72 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Virax Biolabs Group's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-5.87 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Virax Biolabs Group (VRAX) has a EV-to-EBIT of 0.63 as of Aug. 20, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Virax Biolabs Group and its competitors. This is 110% above median its historical median of 0.30. According to the industry distribution chart, Virax Biolabs Group ranks #60 out of 369 companies in the Biotechnology industry, placing it in the top 16.3%.
Is Virax Biolabs Group's EV-to-EBIT too high?
Virax Biolabs Group's current EV-to-EBIT of 0.63 is 110% above median its 10-year median of 0.30. The Biotechnology industry median EV-to-EBIT is 15.95. Virax Biolabs Group's value of 0.63 is 96.1% below this industry median. Based on the distribution chart, Virax Biolabs Group ranks #60 out of 369 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Virax Biolabs Group has a GF Score™ of 45/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's EV-to-EBIT compare to ISCO and PKTX?
According to the Biotechnology industry distribution chart, Virax Biolabs Group ranks #60 out of 369 companies for EV-to-EBIT. This places Virax Biolabs Group in the top 16% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.95. Virax Biolabs Group's value of 0.63 is 96.1% below this benchmark. While the company's 10-year median is 0.30 vs. the industry median of 15.95, Virax Biolabs Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.95, based on 369 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Virax Biolabs Group's current EV-to-EBIT of 0.63 is 96.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Virax Biolabs Group and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Virax Biolabs Group's current EV-to-EBIT is 0.63, which is 110% above median its own 10-year median of 0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.58, compared to a current price of $3.18 — trading 11.2% below its estimated fair value. The current EV-to-EBIT is 0.63, which is 110% above median its 10-year median of 0.30 and 96.1% below the Biotechnology industry median of 15.95. Virax Biolabs Group's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current EV-to-EBIT is 0.63 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Virax Biolabs Group (VRAX) Overvalued in 2026?
Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be undervalued.
The current stock price of $3.18 is trading 11.2% below its estimated GF Value™ of $3.58.
GuruFocus considers Virax Biolabs Group to be Modestly Undervalued.
Key valuation signals for VRAX:
EV-to-EBIT: 0.63 (110% above median its 10-year median of 0.30)
GF Value™: $3.58 vs. price of $3.18 (11.2% below fair value)
Industry Position: 96.1% below the Biotechnology median (#60 of 369)
No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
45GF Score
Get the complete analysis for VRAX
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRAX has been successfully added to your 
